文献速递角膜与眼表疾病小儿眼科与斜弱视

环孢素A阳离子乳剂治疗儿童春季角结膜炎随机研究12个月结果

Twelve-Month Results of Cyclosporine A Cationic Emulsion in a Randomized Study in Patients With Pediatric Vernal Keratoconjunctivitis.
PubMed 文献 · Am J Ophthalmol · 2019-11-23

这项多中心、双盲、随机对照试验对169例4-17岁严重活动性春季角结膜炎患儿进行4个月随机治疗并延续8个月随访,评估环孢素A阳离子乳剂0.1%滴眼液的安全性和疗效。结果显示4个月时角膜荧光素染色评分、补救药物使用、关键症状和生活质量的改善在随后8个月随访中保持稳定,高剂量方案在多数疗效指标上持续更优,安全性良好。

要点

  • CsA CE 0.1%治疗4个月获得的角膜炎、症状和生活质量改善在8个月随访期内保持稳定。
  • 高剂量方案(每日4次)在多数疗效指标上持续优于低剂量方案(每日2次)。
  • 12个月治疗相关不良事件发生率在高剂量组为20.8%、低剂量组为15.7%,最常见为滴眼部位疼痛。

核心结论

  • CsA CE 0.1%滴眼液治疗4个月所获得的角膜炎、症状和生活质量改善在随后8个月随访期间保持稳定。
  • CsA CE继续维持良好的安全性特征,高剂量方案在多数疗效指标上持续提供更大获益。

研究设计与样本

  • 多中心、双盲、随机对照试验的8个月安全性分析,纳入169例4-17岁严重活动性春季角结膜炎患儿。
  • 最初4个月随机分配后,142例进入8个月随访期,CsA CE组维持原方案(每日4次高剂量或每日2次低剂量+每日2次赋形剂),赋形剂组转为两种活性方案之一。

主要发现

  • 角膜荧光素染色评分、补救药物使用、关键VKC症状(畏光、流泪、瘙痒、黏液分泌物)及QUICK问卷评估的生活质量在4个月评估期所见的CsA CE较赋形剂的改善,在8个月随访期内保持稳定。
  • 高剂量方案在多数疗效指标上持续提供更大获益。
  • 12个月研究期间治疗相关治疗中出现的不良事件在高剂量组报告15例(20.8%)、低剂量组11例(15.7%),最常见为滴眼部位疼痛(分别为13.9%和7.1%)。
  • 实验室数据、生命体征、裂隙灯检查、最佳矫正远视力及眼压未提出安全性担忧。

关键数值与推荐

  • CsA CE 0.1%滴眼液高剂量方案为每日4次,低剂量方案为每日2次联合赋形剂每日2次。
  • 治疗相关治疗中出现的不良事件发生率:高剂量组20.8%(15例),低剂量组15.7%(11例)。
  • 滴眼部位疼痛发生率:高剂量组13.9%,低剂量组7.1%。

临床怎么用

  • 对于儿童严重活动性春季角结膜炎,CsA CE 0.1%滴眼液治疗4个月可获得角膜炎、症状和生活质量改善,并在后续8个月维持稳定。
  • 高剂量方案(每日4次)在多数疗效指标上较低剂量方案(每日2次)提供更大获益,但治疗相关不良事件(尤其滴眼部位疼痛)发生率略高。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the safety and efficacy of cyclosporine A cationic emulsion (CsA CE) 0.1% eye drops in pediatric patients with severe active vernal keratoconjunctivitis (VKC). DESIGN: Multicenter, double-masked, randomized controlled trial 8-month safety analysis. METHODS: Of 169 patients (age range, 4-17 years) initially randomized in the 4-month VErnal KeratoconjunctiviTIs Study (VEKTIS), 142 entered the 8-month follow-up period during which CsA CE patients remained on their original regimen (CsA CE 4 times daily [QID, high-dose] or CsA CE twice daily [BID, low-dose] + vehicle BID) and vehicle patients were allocated to one of these 2 active regimens. Main outcome measures were safety, including treatment-emergent adverse events, and efficacy, including corneal fluorescein staining (CFS) score. RESULTS: Improvements in CFS score, rescue medication use, key VKC symptoms (photophobia, tearing, itching, and mucous discharge), and quality of life (QoL) assessed by QUICK questionnaire observed with CsA CE compared with vehicle during the 4-month evaluation period remained stable during the 8-month follow-up period, with the high-dose regimen continuing to provide greater benefits in most efficacy measures. CsA CE was well tolerated. Treatment-related treatment-emergent adverse events during the 12-month study were reported in 15 (20.8%) and 11 (15.7%) of the CsA CE high-dose and low-dose patients, respectively, most commonly instillation site pain (13.9% and 7.1%, respectively). Laboratory data, vital signs, slit lamp examination, best-corrected distance visual acuity, and intraocular pressure raised no safety concerns. CONCLUSIONS: Improvements in keratitis, symptoms, and QoL achieved after CsA CE treatment for 4 months remained stable over the 8-month follow-up period. CsA continued to maintain a favorable safety profile.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bremond-Gignac D, Doan S, Amrane M, et al. Twelve-Month Results of Cyclosporine A Cationic Emulsion in a Randomized Study in Patients With Pediatric Vernal Keratoconjunctivitis. Am J Ophthalmol. 2019. PMID: 31770513. doi:10.1016/j.ajo.2019.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。